4.2 Diabetes, Endocrine & Renal
Key Takeaways
- Metformin is first-line for type 2 diabetes mellitus (T2DM) in most patients; GLP-1 receptor agonists and SGLT2 inhibitors are prioritized when atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease is present.
- Type 1 diabetes mellitus (T1DM) requires lifelong insulin, typically a basal-bolus regimen pairing long-acting basal insulin with rapid-acting prandial insulin and correction dosing.
- Levothyroxine is the standard treatment for hypothyroidism, dosed on a consistent empty-stomach schedule and titrated using thyroid-stimulating hormone (TSH).
- Chronic kidney disease (CKD) requires renal dose adjustment for many medications; metformin and several DOACs are restricted or contraindicated at low estimated glomerular filtration rate (eGFR).
- Hyperkalemia is a life-threatening electrolyte emergency commonly precipitated by renin-angiotensin blockers, MRAs, and potassium supplements, especially in renal impairment.
Endocrine and Renal Care on the NAPLEX
Diabetes, thyroid disease, and chronic kidney disease appear in a large share of NAPLEX patient cases because they coexist with cardiovascular disease and alter how almost every other drug is dosed. The exam expects you to choose therapy by comorbidity, individualize glycemic and blood pressure targets, recognize renal dose adjustments, and manage dangerous electrolyte and acid-base derangements.
Type 2 Diabetes Mellitus (T2DM)
Type 2 diabetes mellitus is a progressive disorder of insulin resistance and relative insulin deficiency. Therapy is individualized to glycemic targets, comorbidities, hypoglycemia risk, weight, cost, and renal function. Glycemic control is monitored chiefly with hemoglobin A1c (HbA1c) and supportive self-monitored or continuous glucose data, with targets individualized (less stringent in older or frail patients).
Major Noninsulin Drug Classes
| Drug class | Examples | Key benefits | Monitoring / cautions |
|---|---|---|---|
| Biguanide | metformin | First-line; weight neutral, low hypoglycemia risk | Hold around iodinated contrast; restricted at low eGFR; GI intolerance, B12 deficiency |
| SGLT2 inhibitors | empagliflozin, dapagliflozin | Cardiovascular, heart failure, and kidney benefit | Genitourinary infections, volume depletion, euglycemic ketoacidosis risk |
| GLP-1 receptor agonists | semaglutide, liraglutide, dulaglutide | Weight loss, cardiovascular benefit | Nausea; caution with personal/family medullary thyroid carcinoma history |
| DPP-4 inhibitors | sitagliptin, linagliptin | Weight neutral, low hypoglycemia | Generally well tolerated; modest efficacy |
| Sulfonylureas | glipizide, glimepiride | Inexpensive, effective | Hypoglycemia and weight gain |
| Thiazolidinedione | pioglitazone | Durable effect | Fluid retention; avoid in heart failure |
Metformin is first-line for most patients. When atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease is present, a GLP-1 receptor agonist or an SGLT2 inhibitor with proven organ benefit is prioritized regardless of HbA1c, because these classes reduce cardiorenal events independent of glucose lowering.
Type 1 Diabetes Mellitus and Insulin Therapy
Type 1 diabetes mellitus is autoimmune beta-cell destruction causing absolute insulin deficiency, so patients require lifelong exogenous insulin. The standard outpatient strategy is basal-bolus therapy: a long-acting basal insulin to control fasting glucose plus rapid-acting prandial (mealtime) insulin with correction doses for hyperglycemia.
| Insulin type | Examples | Onset profile | Typical role |
|---|---|---|---|
| Rapid-acting | lispro, aspart, glulisine | Fast onset, short duration | Mealtime/prandial and correction dosing |
| Short-acting | regular insulin | Slower than rapid-acting | Prandial; intravenous use in inpatient settings |
| Intermediate-acting | NPH | Intermediate onset and duration | Basal coverage in some regimens |
| Long-acting | glargine, detemir, degludec | Slow, relatively flat | Basal coverage |
Safety pearl: The most dangerous insulin adverse effect is hypoglycemia. Counsel patients to recognize symptoms, carry fast-acting carbohydrate, and never skip meals after a prandial dose. Insulin requirements change with illness, exercise, and renal function.
Thyroid Disorders
Hypothyroidism is deficient thyroid hormone production. Standard therapy is levothyroxine, a synthetic T4. Counsel patients to take it consistently on an empty stomach, separated from interacting products such as calcium, iron, and certain antacids, which reduce absorption. Dose is titrated using TSH, the primary monitoring lab.
Hyperthyroidism is excess thyroid hormone. Pharmacologic options include thionamides (methimazole; propylthiouracil is generally preferred only in the first trimester of pregnancy and in thyroid storm) and beta-blockers for symptomatic adrenergic control. Thionamides carry rare but serious risks of agranulocytosis and hepatotoxicity; counsel patients to report fever, sore throat, or jaundice.
Chronic Kidney Disease (CKD) and Renal Dose Adjustment
Chronic kidney disease is sustained reduction in kidney function, staged by estimated glomerular filtration rate (eGFR) and albuminuria. CKD changes pharmacotherapy in two ways: it creates compelling indications (ACEi or ARB for albuminuric CKD; SGLT2 inhibitors for kidney protection) and it requires dose adjustment or avoidance of renally cleared drugs.
| Medication | CKD consideration |
|---|---|
| Metformin | Restricted or contraindicated at low eGFR; assess before initiation and with declining function |
| Many DOACs | Renal dose adjustment required; some agents avoided at very low eGFR |
| NSAIDs | Avoid in significant CKD; worsen renal perfusion and risk acute kidney injury |
| Renally eliminated antimicrobials | Frequent renal dose adjustment (for example, many beta-lactams and vancomycin) |
| Gabapentin/pregabalin | Reduce dose with declining renal function to prevent accumulation |
Exam approach: When a vignette gives an eGFR or rising creatinine, screen the regimen for renally cleared, nephrotoxic, or potassium-raising drugs before answering. "Adjust the dose" or "hold the nephrotoxin" is frequently the best person-centered action.
Electrolyte and Acid-Base Management
Electrolyte emergencies are recurring NAPLEX themes because common cardiorenal drugs cause them.
- Hyperkalemia: elevated serum potassium that can cause fatal arrhythmias. Common drug contributors include ACE inhibitors, ARBs, MRAs, potassium supplements, and potassium-sparing diuretics, with risk amplified by renal impairment. Acute management stabilizes the myocardium and shifts or removes potassium.
- Hypokalemia: low serum potassium, frequently from loop or thiazide diuretics; replace potassium and address the cause.
- Hyponatremia and hypernatremia: sodium disorders requiring careful, controlled correction; overly rapid correction of chronic hyponatremia risks osmotic demyelination.
- Acid-base balance: the exam tests recognition of metabolic acidosis and alkalosis and respiratory compensation; identify the primary disorder and any offending drug or condition before choosing therapy.
Always tie electrolyte findings back to the medication list. The highest-yield link is renin-angiotensin blockade plus an MRA in a patient with reduced renal function producing hyperkalemia.
A 61-year-old patient with type 2 diabetes (HbA1c 7.8%) also has heart failure with reduced ejection fraction and stage 3 chronic kidney disease with preserved-but-reduced eGFR. Metformin is being continued. Which additional agent provides the MOST guideline-concordant cardiorenal benefit?
A patient with hypothyroidism reports that morning levothyroxine has been ineffective despite adherence. Medication review shows the patient takes a calcium carbonate and ferrous sulfate supplement at the same time as levothyroxine each morning. What is the BEST counseling recommendation?
A patient with HFrEF on lisinopril and spironolactone develops a new serum potassium of 6.1 mEq/L with worsening renal function after a recent illness. Which factor is the MOST likely contributor to this finding?